Regeneron/Sanofi's Praluent drug pricing and market rollout

Regeneron/Sanofi's Praluent drug pricing and market rollout The passage only discusses the medical benefits, pricing, and market competition of a new cholesterol drug, with no mention of influential political actors, financial misconduct, or investigative leads. It provides general industry information rather than actionable leads. Key insights: Praluent targets PCSK9 and can lower LDL by up to 60%; Wholesale cost projected at $40 per day ($14,600 per year); Regeneron and Sanofi expect insurer rebates to offset price